CN109486802A - A kind of penicillase mutant and its construction method that enzyme activity improves - Google Patents
A kind of penicillase mutant and its construction method that enzyme activity improves Download PDFInfo
- Publication number
- CN109486802A CN109486802A CN201811601243.5A CN201811601243A CN109486802A CN 109486802 A CN109486802 A CN 109486802A CN 201811601243 A CN201811601243 A CN 201811601243A CN 109486802 A CN109486802 A CN 109486802A
- Authority
- CN
- China
- Prior art keywords
- penicillase
- mutant
- enzyme activity
- enzyme
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to penicillase mutant and its construction method that a kind of enzyme activity improves, belong to gene engineering technology field.The amino acid sequence for the penicillase mutant that enzyme activity of the present invention improves is as shown in SEQ ID NO:1.The present invention uses simple point mutation technology, is based on homology modeling methods, significant for meeting penicillase industry chemical conversion production demand and reduction production cost by selecting specific amino acids to optimize penicillase molecular structure, improving enzyme activity.
Description
Technical field
The present invention relates to penicillase mutant and its construction method that a kind of enzyme activity improves, belong to technique for gene engineering neck
Domain.
Background technique
Since nineteen twenty-nine penicillin invention, antibiotic has played huge effect in terms of preventing and treating bacteriosis.But
It is that, due to long-term a large amount of uses of antibiotic, abuse of antibiotics especially lack of standardizationly results in the bacterial resistance got worse
Property problem.The most important mechanism of bacterial resistance is to generate inactivator, such as beta-lactamase, aminoglycoside modifying enzyme.The interior acyl of β-
Amine enzyme can be such that its amido bond hydrolyzes with the carboxyl covalent bond of beta-lactam, inactivate penicillin and/or cephalosporin.β-is interior
Amidase type is complex, big to having had now been found that more than 300 kinds, and due to super wide spectrum beta-lactam antibiotic
Amount uses, and occurs being resistant to the extended spectrumβ-lactamase (ESBLs) of super wide spectrum beta-lactam antibiotic.According to terminal amino group
Beta-lactamase can be divided into tetra- class of A, B, C and D by the site of acid sequence and encoding gene: SHV belongs to A class, and metalloenzyme belongs to B
Class, AmpC enzyme belong to C class, and 0XA type enzyme belongs to D class.A type and D type enzyme belong to penicillase；C-type enzyme belongs to cephalosporinase；B
Type enzyme keeps activity, therefore referred to as metalloenzyme by metal ion.
The representative enzyme of A type beta-lactamase is TEM type enzyme and SHV type enzyme, they can decompose penicillin medicine, and correct
The hydrolysis ability of spore bacteriums drug is low.A type enzyme can be inhibited by enzyme inhibitors such as clavulanic acid, Sulbactam, Tazobactam Sodiums.
The characteristics of D type beta-lactamase be can decompose it is other can hardly be by zymolytic oxacillin of beta-lactam etc.
Penicillin medicine, referred to as OXA type enzyme.This type of enzyme majority is isolated from Pseudomonas aeruginosa, and hypotype is also very much.Clavulanic acid relaxes
Batan, Tazobactam Sodium etc. have very strong inhibiting effect to this type of enzyme.
Extended spectrumβ-lactamase (ESBLs) is used as the drug resistant main mechanism of Beta-lactam medicine, interior by destroying β-
Amide ring inactivates the molecule antibiotic property of antibacterials, then causes the generation of antibody-resistant bacterium.ESBLs mainly includes following several
Seed type, most commonly seen with SHV type, TEM type, CTX-M type, remaining is various including PER type, GES type, BES type, VEB type etc., respectively
There is some difference for Distribution and hydrolysing activity between enzyme type.Representative enzyme type of the SHV type beta-lactamase as early detection
One of, drug resistant gene is mostly by plasmid-mediated propagation.From nineteen eighty-three since Germany reports the first SHV type ESBL, by
In the end of the year 2016, the SHV form variation body to have come forth in global range is up to more than 180 kinds, and in Nosocomial or Nosocomial Infections
Wide-scale distribution in property microorganism.
SHV type beta-lactamase belongs to A class serine class beta-lactamase, is earliest discovery and enzyme type the most popular
One of.1972, have found SHV-1 type beta-lactamase in one plant of escherichia coli of Germany for the first time, SHV-1 exogenous enzyme with
The 1-5 amino acid that the mode of point mutation influences its expression is replaced, and the substrate spectrum of zymoprotein has been gradually expanded.Nineteen eighty-three,
A kind of SHV type ESBL is had found in the Klebsiella ozaenae of one plant of resistance to cefotaxime, is named as SHV-2, this is first hair
Existing SHV type extended spectrumβ-lactamase.The study found that SHV-2 only has occurred at the 238th compared with SHV-1
Gly238Ser amino acid mutation, and the substitution of this single amino acid changes the activity of SHV-1 type enzyme, then opens up on Antibiotic Resistance
The wide hydrolysing activity to third generation cephalosporins medicine.Hereafter, SHV type ESBLs variant gradually appears, as SHV-2a type,
SHV-3 type, SHV-4 type, SHV-5 type, SHV-12 type etc..
Provide that the sterile production technique of aseptic medicine (including biological products) must assess life using environmental monitoring in GMP
Produce whether environmental Kuznets Curves reach GMP requirement.Monitoring project includes air suspension particle, aerial bacterioplankton, settling bacteria, facility and sets
The microorganism on standby surface and the sanitary condition monitoring of operator etc..Aseptic subpackaged of injection penicillin antibiotics, function
Belong between dust function between energy.Penicillin antibiotics dust is fallen into monitoring culture medium plate, is cultivated reducing in plate
Base sensitivity, and then influence production process environmental monitoring data accurate reliability.Monitoring adds penicillin in culture medium plate
The amount of enzyme, to ensure that environmental monitoring monitoring ware sensitivity of culture medium is suitable for production process environmental monitoring.Develop high activity
Penicillase commercial value with higher.
Heterogenous expression penicillase distinct issues are that expressing quantity is low, penicillin enzyme activity is low.Therefore, rite-directed mutagenesis
Be transformed penicillase, improve enzymatic activities, for meet penicillase industry chemical conversion production demand and reduce production cost have it is important
Meaning.The present invention uses simple point mutation technology, is based on homology modeling methods, optimizes penicillase point by selection specific amino acids
Minor structure improves enzyme activity.
Summary of the invention
A kind of penicillin that enzyme activity improves is provided it is an object of the invention to overcome above-mentioned the deficiencies in the prior art place
Enzyme mutant and its construction method, penicillase mutant enzyme activity with higher of the invention, for meeting penicillase work
Industry is melted into production demand and reduction production cost is significant.
To achieve the above object, the technical scheme adopted by the invention is as follows: the penicillase mutant that a kind of enzyme activity improves, institute
The amino acid sequence of mutant is stated as shown in SEQ ID NO:1.
As the preferred embodiment of penicillase mutant of the present invention, the mutant is in such as SEQ ID NO:2
Shown on the basis of amino acid sequence, the 150th proline is mutated into threonine.
As the preferred embodiment of penicillase mutant of the present invention, amino acid shown in SEQ ID NO:2 is encoded
The nucleotide sequence of sequence is as shown in SEQ ID NO:4.Expressing nucleotide sequence penicillase as shown in SEQ ID NO:4
Engineering bacteria, research institute obtains before being inventor.
Second aspect, the present invention provides the penicillase mutant gene that a kind of enzyme activity improves, on the gene coding
State the penicillase mutant of enzyme activity raising.
As the preferred embodiment of penicillase mutant gene of the present invention, the nucleotide sequence of the gene is such as
Shown in SEQ ID NO:3.
The third aspect, the present invention provides a kind of engineering bacteria, the penicillase of the above-mentioned enzyme activity raising of engineering bacterium expression
Mutant.
Fourth aspect, the present invention provides the preparation methods of above-mentioned engineering bacteria, comprising the following steps: in such as SEQ ID NO:
On the basis of nucleotide sequence shown in 4, the 150th proline is mutated into threonine, mutant is obtained, by recombination
It is connected to expression vector and obtains recombinant plasmid, recombinant plasmid transformed obtains engineering bacteria into DH5 ɑ host strain.
5th aspect, the penicillase mutant improved the present invention provides above-mentioned enzyme activity are preparing answering in penicillase
With.
Compared with prior art, the invention has the benefit that the present invention uses simple point mutation technology, it is based on homologous modeling
Method optimizes penicillase molecular structure by selection specific amino acids, improves enzyme activity, for meeting penicillase industry chemical conversion
Production demand and reduction production cost are significant.
Detailed description of the invention
Fig. 1 is the leaven line chart of penicillase mutant engineering bacteria.
Fig. 2 is the enzyme SDS-PAGE detection figure of supernatant after the broken cracking of penicillase mutant engineering bacteria.
Specific embodiment
Purposes, technical schemes and advantages in order to better illustrate the present invention, below in conjunction with the drawings and specific embodiments pair
The present invention is described further.
1 rite-directed mutagenesis of embodiment
Using the recombinant plasmid containing SEQ ID NO:4 as template plasmid, referring to TaKaRa biological product and operation manual, benefit
With TaKaRa MuTanBEST mutagenesis kit, using the corresponding mutant primer pair of design, the fixed point that PCR amplification goes out BmPGA is prominent
Become sequence, specific steps are as follows:
(1) mutant primer
Forward primer BLAA-150-F is 5 '-GACCTGAACACCGCTATCRHTGGTGACG AACGTGACACC-3 ',
Reverse primer BLAA-150-R is 5 '-GGTGTCACGTTCGTCACCADYGATAGCGG TGTTCAGGTC-3 '.
(2) reaction system (10ul)
10xPfu polymerase buffer 10ul, 10mmol/L dNTP solution 2ul, forward primer 25pmoles, reverse primer
25pmoles, Pfu archaeal dna polymerase 5U, Plasmid DNA template 100-200pg, add water to 100ul.
(3) PCR condition: 94 DEG C of 3min, 94 DEG C of 30s, 55 DEG C of 30s, 72 DEG C of 300s, 30 circulations, 72 DEG C of 10min.
With reference to TAKARA company operation manual, phosphorylation is carried out to 5 ' ends of the PCR DNA segment obtained, then by phosphorus
The mutant primer of acidification carries out recirculation, then converts DH5 α competent cell, and is coated on addition card to receive sulfuric acid mycin anti-
On the LB selectivity plate of raw element, about 20h is cultivated in 37 DEG C of inversions.It can be grown on the LB plate that card receives sulfuric acid mycin antibiotic is added
Exactly conversion out has the transformant of recombinant plasmid.Finally transformant is further cultivated to be expanded to recombinant plasmid,
And extract the recombinant plasmid of amplification.
The mutant plasmid screened is sequenced, determine plasmid obtained be mutated in purpose mutational site and
In non-purpose mutational site, there is no mutation.
The acquisition of 2 engineering bacteria of embodiment
Referring to the method for " Molecular Cloning:A Laboratory guide ", by the plasmid conversion competent escherichia coli cell or ferment after mutation
Female bacterium competence cell, obtain expression mutant enzyme engineering strain, finally by engineered strain be coated on be added sulfuric acid card that
On the LB selectivity plate of mycin antibiotic, about 12-18h is cultivated in 37 DEG C of inversions, kanamycin sulfate antibiotic can be added
What is grown on LB plate is exactly the transformant that conversion has recombinant plasmid.
3 engineering bacterium fermentation culture of embodiment
Single colonie is chosen from LB selectivity culture plate, is seeded in the LB liquid medium of 3mL, kanamycins is added,
To its final concentration of 100 μ g/mL, the 250r/min overnight incubation at 37 DEG C；The culture solution for taking 2mL overnight incubation, is seeded to
In the LB liquid medium of 200mL, 250r/min cultivates 4-6h at 37 DEG C, and OD600 reaches between 1.0-1.6, obtains seed
Bacterium solution.It is linked into 5 liters of fermentors containing 3 liters of TB culture mediums by the inoculum concentration of 1:15, at 37 DEG C, 400rpm, 1.3vvm's
Under fermentation condition, when fermented and cultured to OD600 reaches 25, adjusting temperature is 30 DEG C, is induced with final concentration of 1% IPTG, after
After continuous culture 2 hours, final concentration of 0.5%IPTG induction is added, is cultivated for about 14-16 hours, fermentation ends.
The leaven line chart of engineering bacteria is as shown in Figure 1, abscissa is the time, and ordinate is OD600 numerical value, and numerical value is higher,
Bacterium is dense higher, and OD600 reaches 90 when receiving bacterium, reaches the requirement of industrialized production.Fermentation liquid 8000rpm is centrifuged 20min, collects bacterium
Body, -20 DEG C of preservations.
14-16 hours bacterium solutions of 1ml fermented and cultured are taken, 12000rpm is centrifuged 1min, abandons supernatant, then uses 1ml 20mM phosphorus
Thallus is resuspended in acid potassium salt (PH7.0), then sonicated cells, carries out SDS-PAGE detection.SDS-PAGE is using Laemmli electricity
Swimming method, concentration gum concentration are 5%, resolving gel concentration 8%, are gone back after raw sample mixes with sample-loading buffer, 100 DEG C are boiled 5
Minute carries out loading electrophoresis.
As a result as shown in Fig. 2, the molecular weight of penicillase is about 25KD, 1-B is sampling before induction, and 1-A is to take after inducing
There is positive band after inducing as the result is shown at 25KD, shows penicillase successful expression in sample.
The purifying of 4 mutant enzyme of embodiment
The pretreated affiliation carrier FP-IDA-Ni2+ of 5mL is measured, is fitted into purification column.Sample is according to 1.0BV/h speed mistake
Column.Foreign protein is removed with 1.0BV/h flow velocity with the Washing buffer of 3-5BV, while being existed using protein nucleic acid detector
The protein content that efflux is detected under the conditions of 280nm, until the clarification of Washing buffer and the numerical value of protein nucleic acid detector
Until no longer changing, finally under the monitoring of protein nucleic acid detector 280nm, with the Elution buffer of about 1-2BV with 1-
The speed of 2BV/h elutes purpose enzyme, 4 DEG C of enzyme solution preservations.
The measurement of 5 enzyme hydrolysis vigor of embodiment
1, measuring method
The preparation of penicillin solution: weighing Benzylpenicillin sodium salt (potassium) in right amount, is dissolved into often with phosphate buffer (pH7.0)
The solution of 10,000 unit containing penicillin in 1ml.
The preparation of penicillase dilution: taking the enzyme of penicillase fermentation liquid/after purification, 1000-5000 times is diluted, 37
DEG C preheating.
Measuring method: precision measures penicillin solution 50ml, sets in 100ml measuring bottle, and after being preheated to 37 DEG C, precision is added pre-
The penicillase dilution 25ml of heat is mixed rapidly, is accurately placed 1 hour at 37 DEG C, and precision measures 3ml, is added to immediately smart
[precision measures iodine titration solution (0.05mol/L) 10ml to the iodine titration solution (0.005mol/L) of close measurement, sets in 100ml measuring bottle, uses
Sodium-acetate buffer (pH4.5) is diluted to scale] in 25ml, placed 15 minutes in room temperature dark place, with sodium thiosulfate titrating solution
(0.01mol/L) titration, until adding starch indicator solution when nearly terminal, continues to be titrated to blue disappearance.
Blank test: taking warmed-up penicillin solution 2ml, places 1 hour at 37 DEG C, and above-mentioned iodine titration solution is added in precision
(0.005mol/L) 25ml, then accurate plus penicillase dilution 1ml, places 15 minutes in room temperature dark place, uses thiosulfuric acid
Sodium titrating solution (0.01mol/L) titration.It is calculated as follows:
E=(B-A) × M × F × D × 100
In formula, E is penicillase vigor, unit/(ml hours)；
B is the capacity of above-mentioned sodium thiosulfate titrating solution consumed by blank titration, ml；
A is the capacity of above-mentioned sodium thiosulfate titrating solution consumed by test sample titrates, ml；
M is the concentration of sodium thiosulfate titrating solution, mol/L；
F is under the same conditions that the above-mentioned iodine titration solution (0.005mol/L) of every 1ml is equivalent to the potency of penicillin, single
Position；
D is the extension rate of penicillase solution.
Phosphate buffer (pH7.0): dipotassium hydrogen phosphate 7.36g and potassium dihydrogen phosphate 3.14g are taken, water is added to make into
1000ml。
Sodium-acetate buffer (pH4.5): glacial acetic acid 13.86ml is taken, water is added to make into 250ml；Separately take sodium acetate
27.30g, adds water to make into 200ml, and two liquid are uniformly mixed.
2, test result
The test result of enzyme hydrolysis vigor is as shown in table 1.As shown in Table 1, the enzyme activity of the hydrolysis substrate of mutant enzyme is 1.26
×1010U/L.h, relative to original strain (2.61 × 109U/L.h 4.82 times) are improved.
Table 1
| Bacterium number | Amino acid mutation site | Relative activity (%) |
| Original strain | —— | 100% |
| Penicillase P150T | P150T | 482% |
The preparation of the enzyme TSA solid medium of embodiment 6 and sensitivity test
TSA solid medium is prepared, wherein tryptone 15.0g/L, soy peptone 5.0g/L, sodium chloride 5.0g/L,
Agar 14g/L, pH value 7.5.By configured culture based on high pressure sterilization 25 minutes at 121 DEG C, 50 DEG C are cooled to it, is added
Penicillase is uniformly mixed, so that it is 300,000 units/mL that penicillase, which is dissolved in the concentration in TSA culture medium,.In ultra-clean work
Platform, the enzyme culture medium of 20ml TSA is evenly laid out in plate bottom plate, and cooled and solidified covers plate upper cover.
Penicillin antibiotics 10mg is added into ware, by four 1105 Platings of general rule of " Chinese Pharmacopoeia " version in 2015
Rubbing method tested, calculate the rate of recovery.Micrococcus luteus (G+ coccus), Pi Shi Rolston bacterium (G- bacillus) and mould
The rate of recovery be respectively 100%, 99%, 100%.Penicillin 10mg dust is effectively neutralized as the result is shown, and sensitivity meets training
The employment and suitability test (E & ST) of base is supported, is suitable for penicillin antibiotics surroundings settling bacteria and monitors.
Finally, it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than protects to the present invention
The limitation of range is protected, although the invention is described in detail with reference to the preferred embodiments, those skilled in the art should
Understand, it can be with modification or equivalent replacement of the technical solution of the present invention are made, without departing from the essence of technical solution of the present invention
And range.
SEQUENCE LISTING
<110>Guangzhou Baiyunshan Baidi Biotechnology Co., Ltd.
<120>penicillase mutant and its construction method that a kind of enzyme activity improves
<130> 20181221
<160> 4
<170> PatentIn version 3.3
<210> 1
<211> 267
<212> PRT
<213>artificial sequence
<400> 1
Met Asn Thr Lys Gly Ile Asp Glu Ile Lys Asn Leu Glu Thr Asp Phe
1 5 10 15
Asn Gly Arg Ile Gly Val Tyr Ala Leu Asp Thr Gly Ser Gly Lys Ser
20 25 30
Phe Ser Tyr Arg Ala Asn Glu Arg Phe Pro Leu Cys Ser Ser Phe Lys
35 40 45
Gly Phe Leu Ala Ala Ala Val Leu Lys Gly Ser Gln Asp Asn Arg Leu
50 55 60
Asn Leu Asn Gln Ile Val Asn Tyr Asn Thr Arg Ser Leu Glu Phe His
65 70 75 80
Ser Pro Ile Thr Thr Lys Tyr Lys Asp Asn Gly Met Ser Leu Gly Asp
85 90 95
Met Ala Ala Ala Ala Leu Gln Tyr Ser Asp Asn Gly Ala Thr Asn Ile
100 105 110
Ile Leu Glu Arg Tyr Ile Gly Gly Pro Glu Gly Met Thr Lys Phe Met
115 120 125
Arg Ser Ile Gly Asp Glu Asp Phe Arg Leu Asp Arg Trp Glu Leu Asp
130 135 140
Leu Asn Thr Ala Ile Thr Gly Asp Glu Arg Asp Thr Ser Thr Pro Ala
145 150 155 160
Ala Val Ala Lys Ser Leu Lys Thr Leu Ala Leu Gly Asn Ile Leu Ser
165 170 175
Glu His Glu Lys Glu Thr Tyr Gln Thr Trp Leu Lys Gly Asn Thr Thr
180 185 190
Gly Ala Ala Arg Ile Arg Ala Ser Val Pro Ser Asp Trp Val Val Gly
195 200 205
Asp Lys Thr Gly Ser Cys Gly Ala Tyr Gly Thr Ala Asn Asp Tyr Ala
210 215 220
Val Val Trp Pro Lys Asn Arg Ala Pro Leu Ile Ile Ser Val Tyr Thr
225 230 235 240
Thr Lys Asn Glu Lys Glu Ala Lys His Glu Asp Lys Val Ile Ala Glu
245 250 255
Ala Ser Arg Ile Ala Ile Asp Asn Leu Lys Leu
260 265
<210> 2
<211> 267
<212> PRT
<213>artificial sequence
<400> 2
Met Asn Thr Lys Gly Ile Asp Glu Ile Lys Asn Leu Glu Thr Asp Phe
1 5 10 15
Asn Gly Arg Ile Gly Val Tyr Ala Leu Asp Thr Gly Ser Gly Lys Ser
20 25 30
Phe Ser Tyr Arg Ala Asn Glu Arg Phe Pro Leu Cys Ser Ser Phe Lys
35 40 45
Gly Phe Leu Ala Ala Ala Val Leu Lys Gly Ser Gln Asp Asn Arg Leu
50 55 60
Asn Leu Asn Gln Ile Val Asn Tyr Asn Thr Arg Ser Leu Glu Phe His
65 70 75 80
Ser Pro Ile Thr Thr Lys Tyr Lys Asp Asn Gly Met Ser Leu Gly Asp
85 90 95
Met Ala Ala Ala Ala Leu Gln Tyr Ser Asp Asn Gly Ala Thr Asn Ile
100 105 110
Ile Leu Glu Arg Tyr Ile Gly Gly Pro Glu Gly Met Thr Lys Phe Met
115 120 125
Arg Ser Ile Gly Asp Glu Asp Phe Arg Leu Asp Arg Trp Glu Leu Asp
130 135 140
Leu Asn Thr Ala Ile Pro Gly Asp Glu Arg Asp Thr Ser Thr Pro Ala
145 150 155 160
Ala Val Ala Lys Ser Leu Lys Thr Leu Ala Leu Gly Asn Ile Leu Ser
165 170 175
Glu His Glu Lys Glu Thr Tyr Gln Thr Trp Leu Lys Gly Asn Thr Thr
180 185 190
Gly Ala Ala Arg Ile Arg Ala Ser Val Pro Ser Asp Trp Val Val Gly
195 200 205
Asp Lys Thr Gly Ser Cys Gly Ala Tyr Gly Thr Ala Asn Asp Tyr Ala
210 215 220
Val Val Trp Pro Lys Asn Arg Ala Pro Leu Ile Ile Ser Val Tyr Thr
225 230 235 240
Thr Lys Asn Glu Lys Glu Ala Lys His Glu Asp Lys Val Ile Ala Glu
245 250 255
Ala Ser Arg Ile Ala Ile Asp Asn Leu Lys Leu
260 265
<210> 3
<211> 798
<212> DNA
<213>artificial sequence
<400> 3
atgaacacca aaggtatcga cgaaatcaaa aacctggaaa ccgacttcaa cggtcgtata 60
ggtgtgtacg cactggacac cggttctggt aaatctttct cttaccgtgc taatgagagg 120
ttcccgctgt gctcgtcttt caaaggtttc ctggctgctg ctgttctgaa aggttctcag 180
gacaaccgtc tgaacctgaa ccagatcgtt aactacaaca cccgttctct ggaattccac 240
tctccgatca ccaccaaata caaagacaac ggtatgtctc tgggtgacat ggctgctgct 300
gctctgcagt actctgacaa cggtgctacc aacatcatcc tggaacgtta catcggtggt 360
ccggaaggta tgaccaaatt catgcgttct atcggtgacg aagacttccg tctggaccgt 420
tgggaactgg acctgaacac cgctatcact ggtgacgaac gtgacacctc taccccggct 480
gctgttgcta aatctctgaa aaccctggct ctgggtaaca tcctgtctga acacgaaaaa 540
gaaacctacc agacctggct gaaaggtaac accaccggtg ctgctcgtat ccgtgcttct 600
gttccgtctg actgggttgt tggtgacaaa accggttctt gcggtgctta cggtaccgct 660
aacgactacg ctgttgtttg gccgaaaaac cgtgctccgc tgatcatctc tgtttacacc 720
accaaaaacg aaaaagaagc taaacacgaa gacaaagtta tcgctgaagc ttctcgtatc 780
gctatcgaca acctgaaa 798
<210> 4
<211> 798
<212> DNA
<213>artificial sequence
<400> 4
atgaacacca aaggtatcga cgaaatcaaa aacctggaaa ccgacttcaa cggtcgtata 60
ggtgtgtacg cactggacac cggttctggt aaatctttct cttaccgtgc taatgagagg 120
ttcccgctgt gctcgtcttt caaaggtttc ctggctgctg ctgttctgaa aggttctcag 180
gacaaccgtc tgaacctgaa ccagatcgtt aactacaaca cccgttctct ggaattccac 240
tctccgatca ccaccaaata caaagacaac ggtatgtctc tgggtgacat ggctgctgct 300
gctctgcagt actctgacaa cggtgctacc aacatcatcc tggaacgtta catcggtggt 360
ccggaaggta tgaccaaatt catgcgttct atcggtgacg aagacttccg tctggaccgt 420
tgggaactgg acctgaacac cgctatcccg ggtgacgaac gtgacacctc taccccggct 480
gctgttgcta aatctctgaa aaccctggct ctgggtaaca tcctgtctga acacgaaaaa 540
gaaacctacc agacctggct gaaaggtaac accaccggtg ctgctcgtat ccgtgcttct 600
gttccgtctg actgggttgt tggtgacaaa accggttctt gcggtgctta cggtaccgct 660
aacgactacg ctgttgtttg gccgaaaaac cgtgctccgc tgatcatctc tgtttacacc 720
accaaaaacg aaaaagaagc taaacacgaa gacaaagtta tcgctgaagc ttctcgtatc 780
gctatcgaca acctgaaa 798
Claims (8)
1. the penicillase mutant that a kind of enzyme activity improves, which is characterized in that the amino acid sequence of the mutant such as SEQ ID
Shown in NO:1.
2. penicillase mutant as described in claim 1, which is characterized in that the mutant is in such as SEQ ID NO:2 institute
On the basis of the amino acid sequence shown, the 150th proline is mutated into threonine.
3. penicillase mutant as claimed in claim 2, which is characterized in that amino acid sequence shown in coding SEQ ID NO:2
The nucleotide sequence of column is as shown in SEQ ID NO:4.
4. the penicillase mutant gene that a kind of enzyme activity improves, which is characterized in that the gene coding claims 1 to 3 is appointed
The penicillase mutant that one enzyme activity improves.
5. penicillase mutant gene as claimed in claim 4, which is characterized in that the nucleotide sequence of the gene is such as
Shown in SEQ ID NO:3.
6. a kind of engineering bacteria, which is characterized in that the blueness that any one of described engineering bacterium expression claims 1 to 3 enzyme activity improves
Mycin enzyme mutant.
7. the preparation method of engineering bacteria as claimed in claim 6, which comprises the following steps: in such as SEQ ID
On the basis of nucleotide sequence shown in NO:4, the 150th proline is mutated into threonine, mutant is obtained, will recombinate
Gene is connected to expression vector and obtains recombinant plasmid, and recombinant plasmid transformed obtains engineering bacteria into DH5 ɑ host strain.
8. the penicillase mutant that enzyme activity as claimed in any one of claims 1 to 3 improves is preparing answering in penicillase
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811601243.5A CN109486802B (en) | 2018-12-26 | 2018-12-26 | Penicillin enzyme mutant with improved enzyme activity and construction method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811601243.5A CN109486802B (en) | 2018-12-26 | 2018-12-26 | Penicillin enzyme mutant with improved enzyme activity and construction method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109486802A true CN109486802A (en) | 2019-03-19 |
| CN109486802B CN109486802B (en) | 2020-08-04 |
Family
ID=65712256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811601243.5A Active CN109486802B (en) | 2018-12-26 | 2018-12-26 | Penicillin enzyme mutant with improved enzyme activity and construction method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109486802B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107530406A (en) * | 2015-02-23 | 2018-01-02 | 合成生物制品有限公司 | For protecting the carbapenem enzyme being used together with antibiotic of intestines microbial population |
| WO2018013481A1 (en) * | 2016-07-11 | 2018-01-18 | Board Of Regents, The University Of Texas System | Recombinant polypeptides comprising selenocysteine and method for producing the same |
-
2018
- 2018-12-26 CN CN201811601243.5A patent/CN109486802B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107530406A (en) * | 2015-02-23 | 2018-01-02 | 合成生物制品有限公司 | For protecting the carbapenem enzyme being used together with antibiotic of intestines microbial population |
| WO2018013481A1 (en) * | 2016-07-11 | 2018-01-18 | Board Of Regents, The University Of Texas System | Recombinant polypeptides comprising selenocysteine and method for producing the same |
Non-Patent Citations (2)
| Title |
|---|
| BOYD,D.A.等: "NMC-A[Enterobacter cloacae]", 《GENBANK》 * |
| 姚文兵: "《生物技术制药概论》", 31 August 2015, 中国医药科技出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109486802B (en) | 2020-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nordmann et al. | Biochemical properties of a carbapenem-hydrolyzing beta-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli | |
| Massidda et al. | The Aeromonas hydrophila cphA gene: molecular heterogeneity among class B metallo-beta-lactamases | |
| Walsh et al. | Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia | |
| CN105543201B (en) | A kind of Cephalosporin C acylase mutant | |
| Docquier et al. | CAU-1, a subclass B3 metallo-β-lactamase of low substrate affinity encoded by an ortholog present in the Caulobacter crescentus chromosome | |
| Tsukamoto et al. | Role of lysine‐67 in the active site of class C β‐lactamase from Citrobacter freundii GN346 | |
| WO2017143944A1 (en) | Penicillin g acylase mutant | |
| CN112391365B (en) | Starch branching enzyme mutant with improved catalytic activity and application thereof | |
| Niumsup et al. | Carbapenem-resistant Acinetobacter baumannii producing OXA-23 in Thailand | |
| CN113969290A (en) | Deep sea bacterium-derived alpha-glucosidase QsGH97a and coding gene and application thereof | |
| CN117737037B (en) | N-acetylglucosaminidase mutant De266L delta 6 and preparation and application thereof | |
| CN102925423B (en) | Mutated cephalosporin C acylase | |
| Power et al. | Biochemical and molecular characterization of three new variants of AmpC β-lactamases from Morganella morganii | |
| CN112481244B (en) | Aspartase mutant and coding gene, vector, recombinant bacterium and application thereof | |
| CN109072215A (en) | A kind of Cephalosporin C acylase mutant and its application | |
| CN109337889A (en) | A kind of metallo-β-lactamase mutant and its construction method that enzyme activity improves | |
| CN109486802A (en) | A kind of penicillase mutant and its construction method that enzyme activity improves | |
| CN109576250A (en) | A kind of cephalosporin enzyme mutant and its construction method that enzyme activity improves | |
| Leung et al. | Rarity of transferable beta-lactamase production by Klebsiella species. | |
| Prinarakis et al. | Characterization of a novel SHV α-lactamase variant that resembles the SHV-5 enzyme | |
| CN106350494B (en) | Method for anchoring and optimally preparing methyl parathion hydrolase by using flavin fluorescent protein | |
| CN106399174B (en) | One plant of PA ase and its encoding gene, producing strains and application | |
| Sarvas et al. | The penicillinase of Bacillus licheniformis is an outer membrane protein in Escherichia coli | |
| CN111004794B (en) | Subtilisin E mutant with improved thermal stability and application thereof | |
| Doublet et al. | Molecular and biochemical characterization of the natural chromosome-encoded class A β-lactamase from Pseudomonas luteola |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20191009 Address after: 200000 d2666, No. 200, Huancheng Road, Jiading District, Shanghai Applicant after: Shanghai Junjie Biochemistry Technology Co., Ltd. Address before: 510070 Wanbao North Street, Panyu District, Guangzhou, Guangdong Province, No. 1 Applicant before: Guangzhou Baiyunshan Baidi Biotechnology Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20191029 Address after: 510000 No.1, North Wanbao street, Panyu District, Guangzhou City, Guangdong Province Applicant after: Guangzhou Baiyunshan Baidi Biotechnology Co., Ltd. Applicant after: Shanghai Junjie Biochemistry Technology Co., Ltd. Address before: 200000 d2666, No. 200, Huancheng Road, Jiading District, Shanghai Applicant before: Shanghai Junjie Biochemistry Technology Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |